EdiGene Inc.
Edit

EdiGene Inc.

http://edi-gene.com/
Last activity: 11.04.2019
Active - Reference to Modalis Therapeutics
Categories: EngineeringPlatformPublicScienceTechnologyUniversity
Transformative gene modulation platform with its proprietary, multi-functional Cas proteins. Spin-out from Univ of Tokyo. IPOed in 2020
Mentions
4
Total raised: $30M

Investors 2

Funding Rounds 2

DateSeriesAmountInvestors
10.04.2019Series B$15M-
08.08.2018Series B$15M-

Mentions in press and media 4

DateTitleDescription
11.04.2019Insurance Tech Startup Lemonade Raises $300 Million in Funding: Term Sheet for Thursday, April 11MAKING LEMONADE Softbank is doubling down on Lemonade. Paid Content You can't secure what you can't see From ExtraHop Here’s how Fortune described the startup in 2016: It pools insurance premiums from people who know and trust one another. ...
10.04.2019Daily funding roundup - April 10th, 2019Cullgen received $16M; CleverTap raised $26M; Shift secured $40M; ShopBack landed $45M Bump: Bump is a streetwear iOS marketplace app. Bump has raised $7.5 million in Series A funding led by e.ventures, with participation from Kleiner Perki...
10.04.2019EdiGENE Raises $15M in Series B FundingEdiGENE, a Tokyo, Japan based biotechnology company developing new CRISPR based therapies for treatment of genetic disorders, raised 1.6 Billion-yen (approx. $15M) as the first tranche of Series B round. Participants included new investors ...
08.08.2018Genome Editing Biotech Company EdiGene Raises $15M in Series Pre-B RoundEdiGene Inc., a Beijing, China-based genome editing biotech company, raised approximately $15M in a Series pre-B financing. The round was led by new investor Lilly Asia Ventures (LAV) with participation from new investor Huagai Capital and ...

Reviews 0

Sign up to leave a review

Sign up Log In